Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
308
Total raised
£4.1B
disclosed amounts
This month
£27.8M
raised so far
The financing round was led by Pfizer Ventures and accompanied by pro-rata contributions from existing investors.
"Since our initial investment in Mission seven years ago, the company has grown tremendously and the depth of its scientific expertise and capability has grown alongside it. We are proud to expand our relationship with the company and our scientists are looking forward to a successful collaboration in this important area of research."
Downing Ventures, BGF, Mercia, and Calculus Capital backed the Bedfordshire nanotechnology business in its latest round.
"We are delighted to be bringing such high-profile investors on board, who share our ambitious growth plans for the business. This significant investment is a strong endorsement of the MIPs technology, it will enable us to scale our operations and take the business to the next level. MIPs offer many advantages and provide solutions to enable new applications that push the limit of what was previously possible. This investment will enable us to rapidly expand our operations to service these opportunities and bring exciting new products to the market."
The biotechnology firm has raised £96m in new capital to advance its gene therapy pipeline and manufacturing capabilities.
"The potential of gene therapy to change patients’ lives has never been greater and we are delighted to have leading US and European biotechnology investors join us in this extended Series C financing,"
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."
The grant from Innovate UK is matched by recent seed backing from LifeArc, Parkwalk and UKI2S.
"Bringing validation of our novel gene therapy and the opportunity to accelerate the development of our pipeline, we are delighted to receive this grant from Innovate UK. Ikarovec believes its approach has great potential in the treatment of the debilitating disease of wet AMD, with significant advantages over existing therapies and those in development."
